Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

SPARTAN promotes genetic diversification of the immunoglobulin-variable gene locus in avian DT40 cells.

Nakazato A, Kajita K, Ooka M, Akagawa R, Abe T, Takeda S, Branzei D, Hirota K.

DNA Repair (Amst). 2018 Aug;68:50-57. doi: 10.1016/j.dnarep.2018.06.003. Epub 2018 Jun 18.

PMID:
29935364
2.

Loading and removal of PAHs, fragrance compounds, triclosan and toxicity by composting process from sewage sludge.

Ozaki N, Nakazato A, Nakashima K, Kindaichi T, Ohashi A.

Sci Total Environ. 2017 Dec 15;605-606:860-866. doi: 10.1016/j.scitotenv.2017.06.165. Epub 2017 Jul 3.

PMID:
28683430
3.

Adenine Addition Restores Cell Viability and Butanol Production in Clostridium saccharoperbutylacetonicum N1-4 (ATCC 13564) Cultivated at 37°C.

Kiyoshi K, Kawashima S, Nobuki K, Kadokura T, Nakazato A, Suzuki KI, Nakayama S.

Appl Environ Microbiol. 2017 Mar 17;83(7). pii: e02960-16. doi: 10.1128/AEM.02960-16. Print 2017 Apr 1.

4.

TBP-like protein (TLP) represses myogenesis via inhibition of the myogenin promoter.

Nakazato A, Maeda R, Ishikawa K, Suzuki H, Tamura TA.

Biochem Biophys Res Commun. 2016 Oct 28;479(4):814-819. doi: 10.1016/j.bbrc.2016.09.127. Epub 2016 Sep 25.

PMID:
27680312
5.

Cell surface-associated aggregation-promoting factor from Lactobacillus gasseri SBT2055 facilitates host colonization and competitive exclusion of Campylobacter jejuni.

Nishiyama K, Nakazato A, Ueno S, Seto Y, Kakuda T, Takai S, Yamamoto Y, Mukai T.

Mol Microbiol. 2015 Nov;98(4):712-26. doi: 10.1111/mmi.13153. Epub 2015 Sep 15.

6.

Butanol production from alkali-pretreated rice straw by co-culture of Clostridium thermocellum and Clostridium saccharoperbutylacetonicum.

Kiyoshi K, Furukawa M, Seyama T, Kadokura T, Nakazato A, Nakayama S.

Bioresour Technol. 2015 Jun;186:325-328. doi: 10.1016/j.biortech.2015.03.061. Epub 2015 Mar 19.

PMID:
25818258
7.

Are MMSE and HDS-R neuropsychological tests adequate for screening HIV-associated neurocognitive disorders?

Nakazato A, Tominaga D, Tasato D, Miyagi K, Nakamura H, Haranaga S, Higa F, Tateyama M, Fujita J.

J Infect Chemother. 2014 Mar;20(3):217-9. doi: 10.1016/j.jiac.2013.10.005. Epub 2014 Jan 18.

PMID:
24462448
8.

Isolation of a high malic and low acetic acid-producing sake yeast Saccharomyces cerevisiae strain screened from respiratory inhibitor 2,4-dinitrophenol (DNP)-resistant strains.

Kosugi S, Kiyoshi K, Oba T, Kusumoto K, Kadokura T, Nakazato A, Nakayama S.

J Biosci Bioeng. 2014 Jan;117(1):39-44. doi: 10.1016/j.jbiosc.2013.06.016. Epub 2013 Jul 16.

PMID:
23867095
9.

The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide.

Ago Y, Hiramatsu N, Ishihama T, Hazama K, Hayata-Takano A, Shibasaki Y, Shintani N, Hashimoto H, Kawasaki T, Onoe H, Chaki S, Nakazato A, Baba A, Takuma K, Matsuda T.

Behav Pharmacol. 2013 Feb;24(1):74-7. doi: 10.1097/FBP.0b013e32835cf3e5.

PMID:
23268987
10.

Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.

Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T.

Neuropharmacology. 2013 Feb;65:29-38. doi: 10.1016/j.neuropharm.2012.09.008. Epub 2012 Sep 25.

PMID:
23022081
11.

Decreased hydrogen production leads to selective butanol production in co-cultures of Clostridium thermocellum and Clostridium saccharoperbutylacetonicum strain N1-4.

Nakayama S, Bando Y, Ohnishi A, Kadokura T, Nakazato A.

J Biosci Bioeng. 2013 Feb;115(2):173-5. doi: 10.1016/j.jbiosc.2012.08.020. Epub 2012 Sep 19.

PMID:
22999358
12.

Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor.

Kawasaki T, Marumo T, Shirakami K, Mori T, Doi H, Suzuki M, Watanabe Y, Chaki S, Nakazato A, Ago Y, Hashimoto H, Matsuda T, Baba A, Onoe H.

J Cereb Blood Flow Metab. 2012 Sep;32(9):1737-46. doi: 10.1038/jcbfm.2012.68. Epub 2012 Jun 6.

13.

Characteristics of the high malic acid production mechanism in Saccharomyces cerevisiae sake yeast strain No. 28.

Nakayama S, Tabata K, Oba T, Kusumoto K, Mitsuiki S, Kadokura T, Nakazato A.

J Biosci Bioeng. 2012 Sep;114(3):281-5. doi: 10.1016/j.jbiosc.2012.04.003. Epub 2012 May 8.

PMID:
22575438
14.

R278995/CRA0450, a corticotropin-releasing factor (CRF(1)) receptor antagonist modulates REM sleep measures in rats: Implication for therapeutic indication.

Ahnaou A, Steckler T, Heylen A, Kennis L, Nakazato A, Chaki S, Drinkenburg WH.

Eur J Pharmacol. 2012 Apr 5;680(1-3):63-8. doi: 10.1016/j.ejphar.2012.01.023. Epub 2012 Jan 31.

PMID:
22314225
15.

The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice.

Ago Y, Araki R, Yano K, Kawasaki T, Chaki S, Nakazato A, Onoe H, Hashimoto H, Baba A, Takuma K, Matsuda T.

J Pharmacol Sci. 2012;118(2):295-8. Epub 2012 Jan 27.

16.

Whole-genome sequencing of sake yeast Saccharomyces cerevisiae Kyokai no. 7.

Akao T, Yashiro I, Hosoyama A, Kitagaki H, Horikawa H, Watanabe D, Akada R, Ando Y, Harashima S, Inoue T, Inoue Y, Kajiwara S, Kitamoto K, Kitamoto N, Kobayashi O, Kuhara S, Masubuchi T, Mizoguchi H, Nakao Y, Nakazato A, Namise M, Oba T, Ogata T, Ohta A, Sato M, Shibasaki S, Takatsume Y, Tanimoto S, Tsuboi H, Nishimura A, Yoda K, Ishikawa T, Iwashita K, Fujita N, Shimoi H.

DNA Res. 2011 Dec;18(6):423-34. doi: 10.1093/dnares/dsr029. Epub 2011 Sep 6.

17.

Butanol production from crystalline cellulose by cocultured Clostridium thermocellum and Clostridium saccharoperbutylacetonicum N1-4.

Nakayama S, Kiyoshi K, Kadokura T, Nakazato A.

Appl Environ Microbiol. 2011 Sep;77(18):6470-5. doi: 10.1128/AEM.00706-11. Epub 2011 Jul 15.

18.

Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission.

Ago Y, Araki R, Yano K, Hiramatsu N, Kawasaki T, Chaki S, Nakazato A, Onoe H, Hashimoto H, Baba A, Takuma K, Matsuda T.

Psychopharmacology (Berl). 2011 Oct;217(3):443-52. doi: 10.1007/s00213-011-2295-3. Epub 2011 Apr 13.

PMID:
21487651
19.

A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses.

Shekhar A, Johnson PL, Fitz SD, Nakazato A, Chaki S, Steckler T, Schmidt M.

Int J Neuropsychopharmacol. 2011 Apr;14(3):355-65. doi: 10.1017/S1461145710001355. Epub 2010 Nov 19.

PMID:
21087553
20.

Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice.

Kawasaki T, Ago Y, Yano K, Araki R, Washida Y, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T.

Neuropharmacology. 2011 Feb-Mar;60(2-3):397-404. doi: 10.1016/j.neuropharm.2010.10.009. Epub 2010 Oct 21.

PMID:
20970439
21.

Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.

Sakagami K, Yasuhara A, Chaki S, Yoshikawa R, Kawakita Y, Saito A, Taguchi T, Nakazato A.

Bioorg Med Chem. 2008 Apr 15;16(8):4359-66. doi: 10.1016/j.bmc.2008.02.066. Epub 2008 Feb 26.

PMID:
18348906
22.

Measurement of feline serum interleukin-5 level.

Nakazato A, Momoi Y, Kadoya M, Iwasaki T.

J Vet Med Sci. 2007 Aug;69(8):843-6.

23.

Identification of arginine analogues as antagonists and agonists for the melanocortin-4 receptor.

Nozawa D, Okubo T, Chaki S, Okuyama S, Nakazato A.

Chem Pharm Bull (Tokyo). 2007 Aug;55(8):1232-9.

24.

Synthesis of diphenylmethyl analogues and their affinity for the melanocortin-4 receptor and the serotonin transporter.

Nozawa D, Okubo T, Ishii T, Chaki S, Okuyama S, Nakazato A.

Chem Pharm Bull (Tokyo). 2007 Jul;55(7):1044-50.

25.

Novel piperazines: potent melanocortin-4 receptor antagonists with anxiolytic-like activity.

Nozawa D, Okubo T, Ishii T, Takamori K, Chaki S, Okuyama S, Nakazato A.

Bioorg Med Chem. 2007 Mar 15;15(6):2375-85. Epub 2007 Jan 18.

PMID:
17267226
26.

Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor.

Nozawa D, Okubo T, Ishii T, Kakinuma H, Chaki S, Okuyama S, Nakazato A.

Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005. Epub 2006 Dec 30.

PMID:
17234422
27.
28.

Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.

Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, Ohta H, Nakazato A.

Bioorg Med Chem. 2006 Jun 15;14(12):4193-207. Epub 2006 Feb 17.

PMID:
16487713
29.

Synthesis, in vitro pharmacology, and structure-activity relationships of 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as mGluR2 antagonists.

Yasuhara A, Sakagami K, Yoshikawa R, Chaki S, Nakamura M, Nakazato A.

Bioorg Med Chem. 2006 May 15;14(10):3405-20. Epub 2006 Jan 20.

PMID:
16431115
30.

MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity.

Chaki S, Oshida Y, Ogawa S, Funakoshi T, Shimazaki T, Okubo T, Nakazato A, Okuyama S.

Pharmacol Biochem Behav. 2005 Dec;82(4):621-6. Epub 2005 Dec 6.

PMID:
16337261
31.
32.

Metabolism and disposition of a potent group II metabotropic glutamate receptor agonist, in rats, dogs, and monkeys.

James JK, Nakamura M, Nakazato A, Zhang KE, Cramer M, Brunner J, Cook J, Chen WG.

Drug Metab Dispos. 2005 Sep;33(9):1373-81. Epub 2005 Jun 24.

PMID:
15980102
33.

Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors.

Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A.

Neurosci Lett. 2005 Apr 22;378(3):131-4. Epub 2005 Jan 5.

PMID:
15781145
35.

Design, synthesis, and structure-activity relationships of novel tetracyclic compounds as peripheral benzodiazepine receptor ligands.

Okubo T, Yoshikawa R, Chaki S, Okuyama S, Nakazato A.

Bioorg Med Chem. 2004 Jul 1;12(13):3569-80.

PMID:
15186841
36.

Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.

Wakata N, Nemoto H, Sugimoto H, Nomoto N, Konno S, Hayashi N, Araki Y, Nakazato A.

Clin Neurol Neurosurg. 2004 Mar;106(2):139-41.

PMID:
15003307
37.

MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A.

Neuropharmacology. 2004 Mar;46(4):457-67.

PMID:
14975669
38.

Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T.

Eur J Pharmacol. 2004 Feb 6;485(1-3):145-58.

PMID:
14757135
39.

Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands.

Okubo T, Yoshikawa R, Chaki S, Okuyama S, Nakazato A.

Bioorg Med Chem. 2004 Jan 15;12(2):423-38.

PMID:
14723961
40.
41.

In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).

Suzuki Y, Funakoshi T, Chaki S, Kawashima N, Ogawa S, Kumagai T, Nakazato A, Komurasaki T, Okuyama S.

Life Sci. 2002 Oct 18;71(22):2603-15.

PMID:
12354579
42.

In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.

Funakoshi T, Chaki S, Kawashima N, Suzuki Y, Yoshikawa R, Kumagai T, Nakazato A, Kameo K, Goto M, Okuyama S.

Life Sci. 2002 Aug 9;71(12):1371-84.

PMID:
12127158
43.

Involvement of corticotropin-releasing factor subtype 1 receptor in the acquisition phase of learned helplessness in rats.

Takamori K, Kawashima N, Chaki S, Nakazato A, Kameo K.

Life Sci. 2001 Aug 3;69(11):1241-8.

PMID:
11521748
44.
45.

A case of myasthenia gravis accompanied by erythema elevatum diutinum and rheumatoid arthritis.

Wakata N, Nakazato A, Sugimoto H, Iguchi H, Saito R.

J Neurol. 2001 May;248(5):435-6. No abstract available.

PMID:
11437173
47.

Synthesis and structure-affinity relationships of 4-(5-Aryl-1,2,3,6-tetrahydropyridino)pyrimidine derivatives as corticotropin-releasing factor(1) receptor antagonists.

Kumagai T, Okubo T, Kataoka-Okubo H, Chaki S, Okuyama S, Nakazato A.

Bioorg Med Chem. 2001 May;9(5):1349-55.

PMID:
11377192
48.

Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.

Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, Ito H, Taguchi T, Nakanishi S, Okuyama S.

J Med Chem. 2000 Dec 14;43(25):4893-909.

PMID:
11123999
49.

Divergence of glyceraldehyde-3-phosphate dehydrogenase isozymes in Saccharomyces cerevisiae complex.

Kadokura T, Ito T, Takano S, Nakazato A, Hara H, Watanabe S, Kudo T, Takeda M, Kaneko T.

Syst Appl Microbiol. 2000 Jun;23(2):198-205.

PMID:
10930071
50.

Supplemental Content

Loading ...
Support Center